Ziv-aflibercept may be safe, less expensive alternative to other anti-VEGF treatments

SAN FRANCISCO — Ziv-aflibercept could be an effective and cost-reducing alternative to traditional anti-VEGF therapies in the treatment of neovascular age-related macular degeneration, according to a speaker here.
“The aflibercept molecule and the ziv-aflibercept molecule are the exact same molecule. They bind to the same isoforms of VEGF, they have the exact same molecular weight, and they differ only in the osmolarity of their solution,” Kapil G. Kapoor, MD, said at the American Academy of Ophthalmology annual meeting.
A prospective, randomized, case-control study enrolled

Full Story →